Literature DB >> 19179489

Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway.

Jennifer Kearley1, Karen F Buckland, Sara A Mathie, Clare M Lloyd.   

Abstract

RATIONALE: Although there have been numerous studies on the development of allergen-induced inflammation, the mechanisms leading to resolution of inflammation remain poorly understood. This represents an important consideration because failure to resolve allergen driven inflammation potentially leads to irreversible airway remodeling, characteristic of chronic asthma.
OBJECTIVES: We investigated the resolution of allergic inflammation and identified the factors responsible.
METHODS: BALB/c and C57BL/6 mice were sensitized to ovalbumin and challenged through the airways to induce allergic inflammation. Mice were analyzed at 24 hours and 7 days after the final challenge.
MEASUREMENTS AND MAIN RESULTS: Airway hyperreactivity (AHR) and increased mucus production were present 7 days after the cessation of allergen challenge in BALB/c mice. Persisting AHR correlated with the continued presence of Th2 cells but not eosinophils in the lungs. The role of Th2 cells in maintaining AHR was confirmed using blocking antibodies against T1/ST2, IL-4, and IL-13 during the resolution period. Moreover, AHR in the "Th1 type" C57BL/6 mouse strain was resolved 1 week after allergen challenge, concomitant with clearance of Th2 cells from the lung. Expression of the T1/ST2 ligand, IL-33, also correlated with maintenance of AHR.
CONCLUSIONS: We have used blockade of Th2 function and strain differences to show for the first time that resolution of allergic inflammation and AHR may be dependent on the T1/ST2-IL-33 pathway and the presence of Th2 cells, suggesting they are necessary not only for the development of an allergic response but also for its maintenance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19179489      PMCID: PMC2675564          DOI: 10.1164/rccm.200805-666OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  45 in total

1.  Airway hyperreactivity in exacerbation of chronic asthma is independent of eosinophilic inflammation.

Authors:  Jessica S Siegle; Nicole Hansbro; Cristan Herbert; Ming Yang; Paul S Foster; Rakesh K Kumar
Journal:  Am J Respir Cell Mol Biol       Date:  2006-06-22       Impact factor: 6.914

Review 2.  The eosinophil.

Authors:  Marc E Rothenberg; Simon P Hogan
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

3.  Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33.

Authors:  Tatjana Pecaric-Petkovic; Svetlana A Didichenko; Sacha Kaempfer; Nicole Spiegl; Clemens A Dahinden
Journal:  Blood       Date:  2008-10-27       Impact factor: 22.113

4.  Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system.

Authors:  Yuichi Kondo; Tomohiro Yoshimoto; Koubun Yasuda; Shizue Futatsugi-Yumikura; Mai Morimoto; Nobuki Hayashi; Tomoaki Hoshino; Jiro Fujimoto; Kenji Nakanishi
Journal:  Int Immunol       Date:  2008-04-29       Impact factor: 4.823

5.  Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation.

Authors:  Hiroko Hayakawa; Morisada Hayakawa; Akihiro Kume; Shin-ichi Tominaga
Journal:  J Biol Chem       Date:  2007-07-10       Impact factor: 5.157

6.  IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells.

Authors:  Molly D Smithgall; Michael R Comeau; Bo-Rin Park Yoon; Dawn Kaufman; Richard Armitage; Dirk E Smith
Journal:  Int Immunol       Date:  2008-06-11       Impact factor: 4.823

7.  IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4.

Authors:  Mariola Kurowska-Stolarska; Pete Kewin; Grace Murphy; Remo C Russo; Bartosz Stolarski; Cristiana Couto Garcia; Mousa Komai-Koma; Nick Pitman; Yubin Li; Wanda Niedbala; Andrew N J McKenzie; Mauro M Teixeira; Foo Y Liew; Damo Xu
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

8.  T1/ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation.

Authors:  Niamh E Mangan; Ayan Dasvarma; Andrew N J McKenzie; Padraic G Fallon
Journal:  Eur J Immunol       Date:  2007-05       Impact factor: 5.532

9.  Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent.

Authors:  Jennifer Kearley; Jane E Barker; Douglas S Robinson; Clare M Lloyd
Journal:  J Exp Med       Date:  2005-11-28       Impact factor: 14.307

10.  CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo.

Authors:  C M Lloyd; T Delaney; T Nguyen; J Tian; C Martinez-A; A J Coyle; J C Gutierrez-Ramos
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

View more
  90 in total

Review 1.  Update in asthma 2009.

Authors:  Wendy C Moore; Rodolfo M Pascual
Journal:  Am J Respir Crit Care Med       Date:  2010-06-01       Impact factor: 21.405

Review 2.  IL-33 family members and asthma - bridging innate and adaptive immune responses.

Authors:  Clare M Lloyd
Journal:  Curr Opin Immunol       Date:  2010-11-09       Impact factor: 7.486

3.  TGF-β1 Suppresses IL-33-Induced Mast Cell Function.

Authors:  Victor S Ndaw; Daniel Abebayehu; Andrew J Spence; Patrick A Paez; E Motunrayo Kolawole; Marcela T Taruselli; Heather L Caslin; Alena P Chumanevich; Anuya Paranjape; Bianca Baker; Brian O Barnstein; Tamara T Haque; Kasalina N Kiwanuka; Carole A Oskeritzian; John J Ryan
Journal:  J Immunol       Date:  2017-06-21       Impact factor: 5.422

4.  Identification of the Mhc region as an asthma susceptibility locus in recombinant congenic mice.

Authors:  Martijn C Nawijn; Benoit J A Piavaux; Prescilla V Jeurink; Renée Gras; Marjan A Reinders; Timothy Stearns; Simon Foote; Machteld N Hylkema; Peter C Groot; Ron Korstanje; Antoon J M Van Oosterhout
Journal:  Am J Respir Cell Mol Biol       Date:  2010-10-22       Impact factor: 6.914

5.  Sublingual Immunotherapy Decreases Expression of Interleukin-33 in Children with Allergic Rhinitis.

Authors:  Yuanming Wang; Chuling Li; Yaxiong Xu; Deyu Xu; Gang Yang; Fang Liao; Xianglin Luo
Journal:  Indian J Pediatr       Date:  2018-05-23       Impact factor: 1.967

6.  Small Molecule Mimetics of α-Helical Domain of IRAK2 Attenuate the Proinflammatory Effects of IL-33 in Asthma-like Mouse Models.

Authors:  Jinghong Li; Kunio Saruta; Justin P Dumouchel; Jenna M Magat; Joanna L Thomas; Dariush Ajami; Mitra Rebek; Julius Rebek; Timothy D Bigby
Journal:  J Immunol       Date:  2018-05-04       Impact factor: 5.422

7.  IL-33-induced alterations in murine intestinal function and cytokine responses are MyD88, STAT6, and IL-13 dependent.

Authors:  Zhonghan Yang; Rex Sun; Viktoriya Grinchuk; Joan Antoni Fernández-Blanco; Joan Antoni Fernandez Blanco; Luigi Notari; Jennifer A Bohl; Leon P McLean; Thirumalai R Ramalingam; Thomas A Wynn; Joseph F Urban; Stefanie N Vogel; Terez Shea-Donohue; Aiping Zhao
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-12-20       Impact factor: 4.052

8.  IL-33-dependent induction of allergic lung inflammation by FcγRIII signaling.

Authors:  Melissa Y Tjota; Jesse W Williams; Tiffany Lu; Bryan S Clay; Tiara Byrd; Cara L Hrusch; Donna C Decker; Claudia Alves de Araujo; Paul J Bryce; Anne I Sperling
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808

Review 9.  Disease-associated functions of IL-33: the new kid in the IL-1 family.

Authors:  Foo Y Liew; Nick I Pitman; Iain B McInnes
Journal:  Nat Rev Immunol       Date:  2010-01-18       Impact factor: 53.106

Review 10.  The IL-1 family: regulators of immunity.

Authors:  John E Sims; Dirk E Smith
Journal:  Nat Rev Immunol       Date:  2010-01-18       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.